OraSure Technologies, Inc.

387 articles about OraSure Technologies, Inc.

• OraSure Technologies Provides Update on Its Emergency Use Authorization Application for Its Lab-based Oral Fluid SARS-CoV-2 Antibody Test

  12/21/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Food and Drug Administration (FDA) has requested additional information as part of its review of the Company’s application for Emergency Use Authorization (EUA) for its laboratory-based oral fluid SARS-CoV-2 antibody test. The OraSure SARS-CoV-2 Antibody ELISA is intended for qualitative detection

• OraSure Technologies to Present at the 2020 Evercore ISI HealthCONx Conference

  11/30/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 2020 Evercore ISI HealthCONx Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on December 3, 2020, at approximately 9:40 AM Eastern Standard Time (6:40 AM Pacifi

• OraSure Technologies to Commemorate World AIDS Day by Ringing NASDAQ Closing Bell

  11/30/2020

  OraSure Technologies, Inc., a leader in the fight against HIV, announced its plans to commemorate World AIDS Day.

• OraSure Technologies to Present at the Stephens Annual Investment Conference 2020

  11/12/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Stephens Annual Investment Conference 2020.

• OraSure Technologies, Inc. Announces Third Quarter 2020 Financial Results and Provides Update on COVID-19 Developments

  11/4/2020

  Net Third Quarter Revenues of $48.0Million Increased 33% Year-Over-Year,Driven by $18.4Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing

• OraSure’s DNA Genotek Subsidiary Receives FDA Emergency Use Authorization for its ORAcollect®·RNA Saliva Collection Device for SARS CoV-2Second FDA EUA for the Subsidiary’s Saliva Collection Devices

  11/3/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the use of the ORAcollect®·RNA (OR/ORE-100) saliva collection device for the collection, stabilization and transport of saliva specimens suspected of containing SARS-CoV-2 RNA.

• 

  Biopharma Update on the Novel Coronavirus: November 3

  11/3/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.

• OraSure Technologies to Hold 2020 Third Quarter Earnings Conference Call  Wednesday, November 4, 2020, 5:00 p.m. ET

  10/21/2020

  OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2020 third quarter financial results and certain business developments for 5:00 pm ET on Wednesday, November 4, 2020.

• OraSure’s OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2

  10/19/2020

  OraSure Technologies, Inc. announced its DNA Genotek subsidiary has received Emergency Use Authorization from the U.S. Food and Drug Administration for the use of DNA Genotek’s OMNIgene®·ORAL saliva collection and stabilization device in COVID-19 testing.

• OraSure’s ORAcollect®·RNA Device Included in EUA Granted to Quadrant Biosciences Inc. for COVID-19 Test

  9/24/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its ORAcollect®·RNA saliva collection device has been included in the U.S. Food and Drug Administration Emergency Use Authorization granted to Quadrant Biosciences Inc. for a COVID-19 laboratory test.

• OraSure’s ORAcollect®·RNA Device Included in EUA Granted to MiraDx Inc. for SARS-CoV-2 Test

  9/3/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) collection device was included along with other devices in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to MiraDx Inc., a Los Angeles-based molecular genetics company. This is the fifth EUA

• OraSure Technologies to Present at Upcoming Investor Conferences

  8/27/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the following upcoming investor conferences:

• OraSure Technologies, Inc. Announces 2020 Second Quarter Financial Results and Update on COVID-19 Testing Programs

  8/5/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three and six months ended June 30, 2020.

• OraSure’s OMNIgene®·ORAL Device Included in EUA Granted to Clinical Reference Laboratory for Self-Collected SARS-CoV-2 Saliva Test

  7/31/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), today announced that its OMNIgene®·ORAL (OM-505) saliva collection device is included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the United States, for SARS-CoV-2 testing.

• OraSure Technologies to Hold Second Quarter 2020 Earnings Conference Call on August 5th, 2020

  7/22/2020

  OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2020 second quarter financial results and certain business developments for 5:00 pm ET on Wednesday, August 5, 2020.

• Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

  6/25/2020

  Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis (ASUC). The study, titled: “ Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis (PROTOS Study),

• OraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics

  6/17/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-collection of fecal samples for metabolomics.

• OraSure Technologies Receives BARDA Funding for Coronavirus Antibody ELISA Using Oral Fluid Samples

  6/10/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop an Enzyme-Lin

• OraSure’s Oragene®•Dx included in EUA allowing at-home saliva collection for use with Phosphorus SARS-CoV-2 testThe number of EUAs utilizing OraSure’s saliva collection products continues to grow

  6/8/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced today that Phosphorus Diagnostics, a leader in diagnostic and bioinformatic solutions for clinical next generation sequencing (NGS), was granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration

• OraSure Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares of Common Stock - June 04, 2020

  6/4/2020

  OraSure Technologies, Inc. announced the full exercise by the underwriters of their option to purchase an additional 1,200,000 shares of its common stock in connection with the Company’s previously announced offering that priced on June 2, 2020.